These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1622 related items for PubMed ID: 30098066
21. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232 [Abstract] [Full Text] [Related]
22. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T. Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326 [Abstract] [Full Text] [Related]
23. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Xie M, He CS, Wei SH, Zhang L. Eur J Cancer; 2013 Nov 02; 49(16):3559-72. PubMed ID: 23916913 [Abstract] [Full Text] [Related]
24. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z, Jiang J, He Y. Clin Cancer Res; 2014 May 15; 20(10):2714-26. PubMed ID: 24644001 [Abstract] [Full Text] [Related]
25. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S. Cancer Sci; 2021 Sep 15; 112(9):3784-3795. PubMed ID: 34145930 [Abstract] [Full Text] [Related]
26. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC. Ther Adv Respir Dis; 2020 Sep 15; 14():1753466620915156. PubMed ID: 32552611 [Abstract] [Full Text] [Related]
27. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther; 2012 Oct 15; 11(10):2149-57. PubMed ID: 22844075 [Abstract] [Full Text] [Related]
28. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074 [Abstract] [Full Text] [Related]
29. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Cancer Res; 2021 Mar 01; 81(5):1398-1412. PubMed ID: 33402388 [Abstract] [Full Text] [Related]
30. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Cancer Lett; 2016 Oct 01; 380(2):494-504. PubMed ID: 27450722 [Abstract] [Full Text] [Related]
31. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z. Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520 [Abstract] [Full Text] [Related]
32. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC. Huang J, Lan X, Wang T, Lu H, Cao M, Yan S, Cui Y, Jia D, Cai L, Xing Y. Oncogene; 2020 Feb 29; 39(8):1739-1755. PubMed ID: 31740781 [Abstract] [Full Text] [Related]
33. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474 [Abstract] [Full Text] [Related]
34. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, Zhao C, Zhang L, Cai W, Zhou C. Oncotarget; 2016 Aug 02; 7(31):49948-49960. PubMed ID: 27409677 [Abstract] [Full Text] [Related]
35. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X. Br J Pharmacol; 2017 Oct 02; 174(20):3608-3622. PubMed ID: 28749535 [Abstract] [Full Text] [Related]
36. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL. J Cancer Res Clin Oncol; 2012 Dec 02; 138(12):2069-77. PubMed ID: 22821179 [Abstract] [Full Text] [Related]
37. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. Ye M, Zhang Y, Gao H, Xu Y, Jing P, Wu J, Zhang X, Xiong J, Dong C, Yao L, Zhang J, Zhang J. Clin Cancer Res; 2018 Mar 01; 24(5):1227-1239. PubMed ID: 29229632 [Abstract] [Full Text] [Related]
38. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. PLoS One; 2016 Mar 01; 11(1):e0147344. PubMed ID: 26789630 [Abstract] [Full Text] [Related]
39. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W. Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264 [Abstract] [Full Text] [Related]
40. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B, Zhang WM. Oncotarget; 2015 Dec 29; 6(42):44332-45. PubMed ID: 26554308 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]